France-based Ocean Diagnostics completed a 110‑patient pilot showing its rapid bloodstream pathogen ID test matched conventional blood culture results at 100% and detected additional pathogens missed by culture. The assay uses high-volume sample prep, pan-bacterial PCR, nanopore sequencing and a curated pathogen database to analyze viable bacteria from up to 10 mL of whole blood, delivering results in about five hours with plans to cut that to 3.5 hours. Ocean Dx now plans clinical trials to support CE marking and pursue FDA clearance. Faster, culture‑independent identification could shorten empiric antibiotic use and speed targeted therapy in sepsis care pathways.